AI for the Betterment of Humanity: Spotlight on BioticsAI and the Future of Obstetrics
The introduction of artificial intelligence in various sectors is changing the way we live, work, and interact. Healthcare, in particular, has witnessed some groundbreaking advancements due to AI. One remarkable example is BioticsAI, an AI-powered software that not only validates the quality and completeness of fetal anomaly screenings but also pinpoints fetal vulnerabilities and automates the generation of reports. With BioticsAI’s Clinical Intelligence Platform, obstetricians are empowered, enabling them to prioritize their patients’ well-being.
The world currently faces a concerning shortage of obstetrics professionals. At a time when their expertise is crucial, these professionals find themselves buried under administrative tasks, leaving them with limited time for patient care. BioticsAI is designed to alleviate this issue. The platform enhances efficiency and productivity, allowing doctors to focus on providing the highest quality care. This isn’t just about streamlining processes; it’s about ensuring that every expectant mother receives comprehensive and patient-centric care.
BioticsAI’s capability to accurately identify errors in fetal ultrasound screenings is transformative. By localizing problematic anatomical views and automatically producing high-quality documentation, patient experiences are significantly improved. This real-time feedback to clinicians is invaluable. As noted in StartUp Health, the sheer volume of daily screenings demands efficient tools like BioticsAI. The platform supercharges prenatal ultrasound, providing ultrasound technicians with instantaneous secondary opinions. This, in turn, offers a much-needed support system for overworked OB/GYNs.
Delving into BioticsAI’s inception, the story traces back to Robhy Bustami and Salman Khan. Their shared experiences and personal stories of medical misdiagnoses in healthcare became the foundation for BioticsAI. With AI, they sought to rectify the inherent challenges of the current system, providing an additional layer of precision in prenatal screenings.
Prenatal ultrasounds have become standard practice for expectant mothers. Especially the 20-week ultrasound, which provides a comprehensive view of the baby’s health. During this time, any fetal abnormalities can be detected. However, there’s a significant challenge: a substantial shortage of OB/GYNs to interpret these crucial scans. Current projections suggest that by 2050, the US could face a deficit of 22,000 OB/GYNs due to factors like an aging workforce, prolonged work hours, and the prevalence of malpractice suits. This shortage, coupled with additional annual reporting requirements, has led to clinician burnout, further detracting from the primary reason many entered the profession: patient care.
BioticsAI aims to bridge this gap. The startup employs AI to enhance the interpretation of 2nd-trimester ultrasounds, streamlining compliance workflows and giving physicians more time for patient care. Bustami and Khan’s initial journey involved feeding their machine learning algorithms with over a million ultrasound images to recognize abnormalities accurately. Once confident in their AI engine, they launched BioticsAI, which now serves as an automatic second opinion, drastically reducing the chances of misdiagnosis.
The impact of BioticsAI extends beyond error reduction. It also addresses a significant administrative challenge: documentation. “We’re assisting doctors and techs, we’re not replacing them,” Khan emphasized. By automating many of the labor-intensive processes, such as capturing images and storing them in the PACS system, BioticsAI has shown it can cut down reporting time considerably.
BioticsAI’s potential doesn’t go unnoticed. Investors recognize the promise of the platform. Bustami’s technical prowess combined with Khan’s business development skills presents a dynamic duo capable of revolutionizing the field. Their shared commitment, rooted in genuine friendship, positions them for success even in the face of challenges.
Furthermore, the global implications of BioticsAI cannot be overstated. The platform’s capability could transform prenatal care in regions currently devoid of such services. Ultimately, BioticsAI’s potential impact extends beyond just the United States; its innovative approach could ensure that millions worldwide receive essential prenatal care.
A testament to BioticsAI’s groundbreaking approach is their recent recognition at TechCrunch Disrupt 2023. Among 20 startups competing for the coveted Startup Battlefield Cup and $100,000 prize, BioticsAI emerged victoriously. Their AI-based platform seamlessly integrates with ultrasound machines, preventing fetal malformation misdiagnoses with impressive accuracy. While their current focus remains on second-trimester anomaly screenings, the horizon looks bright with potential expansions into fields like gynecology, urology, and neonatology. The future beckons, and BioticsAI stands poised to redefine reproductive health diagnostics with AI.
BluShark Media is your trusted pilot to navigate the ocean of web3, blockchain, NFTs, gaming & AI information.
